At this first level of analysis, we found a high degree of heterogeneity in frequencies of naïve-, CM-, EM-, and TEMRA CD4+ T cells between patients with MS and, therefore, grouped patients into low (group 1), intermediate (group 2), and high (group 3) level of CD4+ T-cell senescence. Here, CD4 is linked to myeloid sarcoma.